Becton Dickinson and Company (BDX)vsFemasys Inc (FEMY)
BDX
Becton Dickinson and Company
$151.16
+1.07%
HEALTHCARE · Cap: $39.80B
FEMY
Femasys Inc
$0.37
-1.75%
HEALTHCARE · Cap: $925,180
Smart Verdict
WallStSmart Research — data-driven comparison
Becton Dickinson and Company generates 969115% more annual revenue ($22.23B vs $2.29M). BDX leads profitability with a 5.1% profit margin vs 0.0%. BDX earns a higher WallStSmart Score of 65/100 (B-).
BDX
Strong Buy65
out of 100
Grade: B-
FEMY
Hold38
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+9.9%
Fair Value
$200.45
Current Price
$151.16
$49.29 discount
Intrinsic value data unavailable for FEMY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Earnings expanding 28.6% YoY
Revenue surging 39.9% year-over-year
Areas to Watch
Moderate valuation
ROE of 4.7% — below average capital efficiency
5.1% margin — thin
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : BDX
The strongest argument for BDX centers on Price/Book, EPS Growth. PEG of 1.11 suggests the stock is reasonably priced for its growth.
Bull Case : FEMY
The strongest argument for FEMY centers on Revenue Growth. Revenue growth of 39.9% demonstrates continued momentum.
Bear Case : BDX
The primary concerns for BDX are P/E Ratio, Return on Equity, Profit Margin.
Bear Case : FEMY
The primary concerns for FEMY are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
BDX profiles as a value stock while FEMY is a hypergrowth play — different risk/reward profiles.
BDX carries more volatility with a beta of 0.28 — expect wider price swings.
FEMY is growing revenue faster at 39.9% — sustainability is the question.
BDX generates stronger free cash flow (546M), providing more financial flexibility.
Bottom Line
BDX scores higher overall (65/100 vs 38/100). Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Becton Dickinson and Company
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.
Visit Website →Femasys Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Femasys Inc. is an innovative medical technology company dedicated to transforming women's healthcare through its proprietary solutions for diagnosing and treating gynecological conditions. With a focus on non-surgical alternatives, Femasys is addressing prevalent issues such as uterine fibroids and contraception, positioning itself as a key player in the growing field of women’s health. As demand for minimally invasive treatments continues to rise, the company is strategically equipped to enhance patient outcomes and efficiency in healthcare delivery. By concentrating on significant unmet needs, Femasys aims to set new standards for care in this essential sector.
Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?